Brian B. Hansen
Known title: EVP & CHIEF COMMERCIAL OFFICERCIK: 0001542377
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating. Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.
Transaction History
| SENS | ▼ Sell | Tax Withholding | 5,420 | $39K | 6/15/2026 | View on chart |
| SENS | ▲ Buy | Grant | 90,253 | $0 | 5/19/2026 | View on chart |
| SENS | ▲ Buy | Grant | 842,084 | $0 | 5/23/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 406 | $0 | 11/27/2023 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 135 | $3K | 11/27/2023 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 54 | $983 | 11/15/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 474 | $0 | 11/15/2023 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 157 | $3K | 11/15/2023 | View on chart |
| TNDM | ▲ Buy | Grant | 1 | $15 | 11/15/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 162 | $0 | 11/15/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 407 | $0 | 8/28/2023 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 135 | $4K | 8/28/2023 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 54 | $2K | 8/15/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 474 | $0 | 8/15/2023 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 157 | $5K | 8/15/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 162 | $0 | 8/15/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 406 | $0 | 5/30/2023 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 135 | $4K | 5/30/2023 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 54 | $2K | 5/15/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 1,897 | $0 | 5/15/2023 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 627 | $20K | 5/15/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 163 | $0 | 5/15/2023 | View on chart |
| TNDM | ▲ Buy | Grant | 631 | $17K | 5/15/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 407 | $0 | 2/27/2023 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 154 | $6K | 2/27/2023 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 62 | $3K | 2/15/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 162 | $0 | 2/15/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 406 | $0 | 11/28/2022 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 132 | $5K | 11/28/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 163 | $0 | 11/15/2022 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 53 | $2K | 11/15/2022 | View on chart |
| TNDM | ▲ Buy | Grant | 1 | $36 | 11/15/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 407 | $0 | 8/29/2022 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 133 | $6K | 8/29/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 162 | $0 | 8/15/2022 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 53 | $3K | 8/15/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 406 | $0 | 5/27/2022 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 132 | $9K | 5/27/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 650 | $0 | 5/16/2022 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 211 | $16K | 5/16/2022 | View on chart |
| TNDM | ▲ Buy | Grant | 306 | $19K | 5/16/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 407 | $0 | 2/28/2022 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 146 | $16K | 2/28/2022 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 193 | $25K | 11/29/2021 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 406 | $0 | 11/29/2021 | View on chart |
| TNDM | ▼ Sell | Open Market | 2,180 | $262K | 9/13/2021 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 2,180 | $20K | 9/13/2021 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 30,000 | $1.5M | 9/13/2021 | View on chart |
| TNDM | ▼ Sell | Open Market | 1,900 | $231K | 9/13/2021 | View on chart |
| TNDM | ▼ Sell | Open Market | 11,800 | $1.4M | 9/13/2021 | View on chart |
| TNDM | ▼ Sell | Open Market | 1,300 | $159K | 9/13/2021 | View on chart |
| TNDM | ▼ Sell | Open Market | 15,000 | $1.8M | 9/13/2021 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 407 | $0 | 8/27/2021 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 133 | $15K | 8/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Beta Bionics and Senseonics announce iLet-Eversense 365 integration
Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.
Beta Bionics and Senseonics announce iLet-Eversense 365 integration. Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.